Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock. A simpler dosage method Is Roche stock a buy? But good news for Roche is bad news for the companies that now seem to have the weight-loss drug market to themselves. Shares of Eli Lilly (LLY -2.62%) were down 2.8% today, and Novo Nordisk (NVO -3.51%) lost 4%. This isn't great news for Lilly and Novo Nordisk, both of which have blockbuster GLP-1 drugs on the market -- Zepbound and Mounjaro for Lilly, and Ozempic and Wegovy for No ...

Roche has a robust Phase III clinical development programme for Vabysmo. The programme includes AVONELLE-X (NCT04777201), an extension study of TENAYA (NCT03823287) and LUCERNE (NCT03823300), evaluating the long-term safety and tolerability of Vabysmo in neovascular or 'wet' agerelated macular degeneration (nAMD).17 Roche has also initiated several Phase IV studies, including the ELEVATUM (NCT05224102) study of Vabysmo in underrepresented patient populations with diabetic macular edema, the SALWEEN study of ...

Roche announced strong early stage data from its weight-loss drug CT-996. The once-daily pill delivered placebo-adjusted mean weight loss of 6.1% in obesity patients without diabetes. CT-996 represent possible competition to popular weight-loss drugs Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Roche Added Drug To Pipeline With Carmot Therapeutics Acquisition tips@investopedia.com A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, ...

Topline Roche said it had promising results from an ongoing trial for its obesity pill and would progress to ... [+] midstage trials. Roche said patients taking its experimental once-daily oral drug, CT-996, for four weeks lost an average of 6.1% of their starting bodyweight compared to patients who received a placebo. The CT-996 drug belongs to the same family of GLP-1 hormone mimicking drugs as blockbuster injections like Ozempic, Wegovy, Mounjaro and Zepbound and Roche said the study indicates it is safe ...

Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate. The Swiss pharmaceutical giant said Wednesday that a second drug candidate from its purchase of Carmot Therapeutics indicated positive results, further heating up competition in the weight loss drug market. Roche shares jumped in early deals and were trading 5.87% higher as of 11:17 a.m. London time. Shares of Wegovy-maker Novo Nordisk fell 3.77%, while Zepbound pro ...

After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001)1 Pharmacokinetic data supports a once-daily oral dosing regimen for CT-9961 The safety and tolerability profile was consistent with other oral GLP-1 receptor agonists and no unexpected safety signals were observed1 Obesity is one of the most urgent health challenges in the world with extensive comorbidities, such as type 2 diabetes, cardiovascular disease, liver disease, an ...

More on the News The integrated AI-enabled predictive algorithms of the CGM can identify potential risks of hypoglycemia within 30 minutes, continually forecast the development of glucose levels over the next two hours and evaluate the risk of hypoglycemia over the night. Accu-Chek SmartGuide is a CGM solution developed by Roche Holding to provide accurate real-time glucose readings and predictions for different timeframes. The solution includes three elements —the Accu-Chek SmartGuide CGM sensor, the Accu- ...

The collaboration leverages Remix's REMaster™ platform to discover novel drugs for a diverse range of target classes "Completing this milestone further demonstrates the power and potential of the REMaster platform, purposebuilt to identify novel, druggable RNA processing mechanisms," said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix. "We are incredibly proud of the research team's accomplishments, which bring us closer towards potentially developing new, small molecule medicines for p ...

The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate1 real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy. The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur. The solution is set to launch in selected European markets in the coming months. Clinical evaluations have demonstrated the new CGM solution's high system accuracy, with an o ...

The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeks Susvimo offers the first alternative to regular eye injections that are standard of care for nAMD, which impacts 20 million people worldwide and can cause blindness if left untreated By continuously delivering medicine to the eye through a refillable implant, Susvimo is the first and only approved nAMD treatment shown to maintain vision with two refills a year "We are pleased ...